Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics Inc.

Insiders have been trading these 5 stocks: (($MDGL)), (($CLNN)), (($COR)), (($SQNS)) and (($FOLD)). Here is a breakdown of their recent trades and ...

Market Cap	$2.84B	P/E Ratio	129.91
52W High	$14.38	52W Low	$5.51
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	41.9%	52W Position	99.0%
Overall Score	53	Value Score	20
Quality Score	65	Technical Score	75

EPS Current Est	$0.11	EPS Next Est	$0.41
EPS Growth Est	+272.7%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FOLD	$14.29	0.00%	7.78M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FOLD	$14.29	0%	7.78M
3
4
5
6

FOLD

FOLD

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Amicus Therapeutics Inc. Data in Excel

Get Amicus Therapeutics Inc. Data in Excel